Thursday 12 September 2019

UMC Utrecht

Deadline for registration: 1 September 2019


The theme of the 2019 edition will be Structural Vaccinology

Previous editions covered topics like Novel Vaccine Platforms, The powerful contribution of vectors to vaccine-induced immunity, Vaccination in the Elderly, Maternal vaccination, Vector-borne diseases, Vaccines and re-emerging infections and Innovative vector approaches in vaccination.

The symposium will be open for all interested at no charge, it is however necessary to register below.

Program & abstracts

Click here for a PDF file of all abstracts combined.

09.30   Andrew Ward, Integrative Structural Biology, Scripps Institute, San Diego
“Using the broad resolving power of the electron microscope to drive vaccine development”

10.10   Rogier Sanders, Amsterdam UMC and Weill Cornell Medical Center, New York
“Structure-based HIV-1 vaccine design”

10.40   Berend Jan Bosch, UU, Faculty of Veterinary Medicine
“Interrogating humoral immune responses to find key protective antibodies against coronaviruses”

11.10   Break

11.30   Hans Langedijk, Janssen, Leiden
“Stabilization of conserved metastable structural elements in class I fusion proteins for optimal vaccine design”

12.00   Joost Snijder, UU, Faculty of Science/Seattle
“Integrating MS and cryoEM to monitor glycosylation of viral antigens and its role in antigen-antibody interactions”

12.30   Robert de Vries, UU, Faculty of Science
“Understanding Influenza A virus receptor specificity is essential for H3N2 vaccine development”

13.00   Lunch

13.40   Henderik W. Frijlink, RUG, Groningen Research Institute of Pharmacy
"Dry vaccines for pulmonary administration"


14.10   Matthijs Raadsen, EUR Viroscience
“Clinical development of a novel vaccine for MERS coronavirus based on the Modified Vaccinia Ankara (MVA) vector“

14.25   Break

15.00   Philip Brouwer, Amsterdam UMC
“A two-component nanoparticle vaccine candidate presenting stabilized Lassavirus glycoproteins”

15.15   Kwinten Sliepen, Amsterdam UMC
“Novel hepatitis C virus vaccine candidates based on E1E2 glycoproteins displayed on designed two-component nanoparticles”